Meeting Minutes: Drug Formulary Committee - DRAFT

Date and time: Nov. 17, 2021, 5:15-9 p.m.
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD; Kyle Lehenbauer, MD; Mary Mescher Benbenek, APRN, PhD; Kelly Ruby, PharmD; Monica Brands, RPh; Kathryn Lombardo, MD; Margaret Artz, RPh, PhD; Kathryn Montag-Shafer, PharmD
- **Members absent:** Tsewang Ngodup, MD; Tim Cernohous, PharmD; James Phillips, MD; Ramona Powell, PharmD; Michael Sprehe, MD
- **DHS staff present:** Dave Hoang, PharmD, MBA; Chad Hope, PharmD; Nathan Chomilo, MD
- **Others in attendance:** Ariane Casey, PharmD; Naana Osei-Boateng, PharmD; Umang Patel, PharmD

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- Minutes from the September 2021 meeting were reviewed and accepted as presented.

DHS Housekeeping

Old Business – None

New Business – None

- The Department of Human Services (DHS) shared information about an upcoming meeting to discuss the Drug Formulary Committee composition and representation on Nov. 29, 2021. The meeting is open to the public.
- The committee recognized Nathan Chomilo, MD, for being honored by both the Minnesota Medical Association and the Minnesota American College of Physician’s conferences at their 2021 meetings.
- Dave Hoang introduced Han Kwon, incoming Kepro’s prior authorization pharmacist and recognized Ariane Casey, outgoing Kepro’s prior authorization pharmacist. Kepro is the contracted prior authorization agent for DHS.
The committee discussed the proposed criteria for drugs with new or expanded indication presented by DHS and approved the proposed criteria by unanimous vote.

New Specialty Drugs for Continued PA

- The committee discussed Onureg and recommended to DHS by a unanimous vote that Onureg remain on PA with the proposed criteria.
- The committee discussed Gavreto and recommended to DHS by a unanimous vote that Gavreto remain on PA with the proposed criteria.
- The committee discussed Uplizna and recommended to DHS by a unanimous vote that Uplizna remain on PA with the proposed criteria.
- The committee discussed Verquvo and recommended to DHS by a unanimous vote that Verquvo remain on PA with the proposed criteria, with the following changes:
  - 5th bullet of Initial Approval Criteria: add Entresto to the list of guideline-directed therapy
- The committee discussed Tepmetko and recommended to DHS by a unanimous vote that Tepmetko remain on PA with the proposed criteria.
- The committee discussed Lupkynis and recommended to DHS by a unanimous vote that Lupkynis remain on PA with the proposed criteria.
- The committee discussed Zokinvy and recommended to DHS by a unanimous vote that Zokinvy remain on PA with the proposed criteria.
- The committee discussed Danyleanza and recommended to DHS by a unanimous vote that Danyleanza remain on PA with the proposed criteria.
- The committee discussed Ukoniq and recommended to DHS by a unanimous vote that Ukoniq remain on PA with the proposed criteria.
- The committee discussed Amondys-45 and recommended to DHS by a unanimous vote that Amondys-45 remain on PA with the proposed criteria.
- The committee discussed Cosela and recommended to DHS by a unanimous vote that Cosela remain on PA with the proposed criteria.
- The committee discussed Margenza and recommended to DHS by a unanimous vote that Margenza remain on PA with the proposed criteria, with the following changes:
  - 7th bullet of Approval Criteria: Amend to read: “Prescriber has performed a pregnancy test AND discussed appropriate contraception in patients of reproductive potential.”
- The committee discussed Fotivda and recommended to DHS by a unanimous vote that Fotivda remain on PA with the proposed criteria, with the following changes:
  - 10th bullet of Initial Approval Criteria: amend to include male patients with female partners of reproductive potential.
- The committee discussed Jemperli and recommended to DHS by a unanimous vote that Jemperli remain on PA with the proposed criteria, with the following changes:
  - 11th bullet of Initial Approval Criteria: remove the word “females” and replace with “patients.”
The committee discussed Rybrevant and recommended to DHS by a unanimous vote that Rybrevant remain on PA with the proposed criteria, with the following changes:
  - 8th and 9th bullets of Initial Approval Criteria: remove the word “female.”

The committee discussed Myfembree and recommended to DHS by a unanimous vote that Myfembree remain on PA with the proposed criteria.

The committee discussed Orgovyx and recommended to DHS by a unanimous vote that Orgovyx remain on PA with the proposed criteria.

The committee discussed Lumakras and recommended to DHS by a unanimous vote that Lumakras remain on PA with the proposed criteria.

**Consent Agenda Item**

The committee discussed Dupixent under the Consent Agenda Policy and recommended to DHS by a unanimous vote that Dupixent remain on PA with the proposed updated criteria.

**Preferred Drug List**

The committee discussed the Immunomodulators, Atopic Dermatitis therapeutic class under the Consent Agenda Policy and recommended the following to DHS by a unanimous vote:
  - DUPIXENT (SUBCUTANE.) to be moved to PREFERRED status on the MN Uniform Preferred Drug List.

**Adjournment**

The meeting was adjourned at approximately 8:41 p.m. Central time.